Disagree
Home Boehringer Ingelheim Boehringer Ingelheim
Micardis Plus 92.5
Micardis Plus 92.5 - Boehringer Ingelheim

Micardis Plus 92.5 - Boehringer Ingelheim

Brand:
Category:
Substance:
Dosage:
92.5 mg/tab
Package:
28 tablets
Price:
£24.00 - £24.00
See options
Product Overview

Mix of two substances: Telmisartan, an antihypertensive agent, shows potential in cancer therapy by inhibiting esophageal squamous cell carcinoma growth. It promotes cell-cycle arrest in the S-phase by targeting proteins like cyclin A2 and CDK2 and affects ErbB3 receptors, marking its promise beyond hypertension management. In transplant recipients, hydrochlorothiazide (HCTZ) is linked to a two-fold higher risk of squamous cell carcinoma (SCC) due to its photosensitizing properties. The drug’s impact on basal cell carcinoma (BCC) is negligible, but SCC’s aggressive nature highlights the importance of sun protection and regular skin checks for these patients.

References:

Matsui, T., Chiyo, T., Kobara, H., Fujihara, S., Fujita, K., Namima, D., Nakahara, M., Kobayashi, N., Nishiyama, N., Yachida, T., Morishita, A., Iwama, H., and Masaki, T. (2019) Telmisartan inhibits cell proliferation and tumor growth of esophageal squamous cell carcinoma by inducing S-phase arrest in vitro and in vivo', International Journal of Molecular Sciences.

Letellier, T., Leborgne, F., Kerleau, C., Gaultier, A., Dantal, J., & Ville, S., on behalf of the Divat Consortium. (2020) 'Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients', Clinical Journal of the American Society of Nephrology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Micardis Plus 92.5 by Boehringer Ingelheim, consult with your doctor or healthcare professional.

Products
Show more
Explore More Products
FAQ
What is the risk of SCC with HCTZ use in transplant recipients?
HCTZ use doubles the risk of SCC in kidney transplant recipients compared to those not using the drug.
References:

Letellier, T., Leborgne, F., Kerleau, C., Gaultier, A., Dantal, J., & Ville, S., on behalf of the Divat Consortium. (2020) 'Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients', Clinical Journal of the American Society of Nephrology.

Why are transplant recipients more vulnerable to SCC?
Immunosuppressive therapy in transplant recipients weakens the immune system, making them more susceptible to SCC. HCTZ amplifies this risk.
References:

Letellier, T., Leborgne, F., Kerleau, C., Gaultier, A., Dantal, J., & Ville, S., on behalf of the Divat Consortium. (2020) 'Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients', Clinical Journal of the American Society of Nephrology.

What is the potential role of telmisartan in cancer treatment?
Recent studies suggest telmisartan may slow the growth of esophageal squamous cell carcinoma (ESCC) by promoting cell-cycle arrest in the S-phase. It targets proteins like cyclin A2 and CDK2 and influences ErbB3 receptors, making it a promising candidate for targeted cancer therapies.
References:

Matsui, T., Chiyo, T., Kobara, H., Fujihara, S., Fujita, K., Namima, D., Nakahara, M., Kobayashi, N., Nishiyama, N., Yachida, T., Morishita, A., Iwama, H., and Masaki, T. (2019) Telmisartan inhibits cell proliferation and tumor growth of esophageal squamous cell carcinoma by inducing S-phase arrest in vitro and in vivo', International Journal of Molecular Sciences.